Chi Van Dang, M.D., Ph.D.

Chi Van Dang, M.D., Ph.D.

Laboratory

The Dang Laboratory

Contact

215-898-3956
cdang@wistar.org

Professor, Molecular & Cellular Oncogenesis Program

Strategic Advisor to the President

About the Scientist

Dang helped define the complex functions of the MYC oncogene, a central switch in human cancer, identifying key domains mediating Myc transcription factor activity.

Dang received his B.S. in Chemistry from the University of Michigan, Ann Arbor and Ph.D. in Chemistry from Georgetown University, Washington, DC. He earned an M.D. degree from the Johns Hopkins University School of Medicine, and was an Osler Medical Resident at Johns Hopkins Hospital. He received Hematology-Oncology training at UCSF, where he first worked on MYC, and returned to Johns Hopkins as Assistant Professor of Medicine.

Dang is Scientific Director of the Ludwig Institute for Cancer Research and joined The Wistar Institute as a Professor in July of 2017. He is a member of the National Academy of Medicine and a fellow of the American Academy of Arts & Sciences, and previously served as director of the Abramson Cancer Center, University of Pennsylvania.

View Publications

The Dang Laboratory

The Dang laboratory has contributed to the understanding of the function of the MYC cancer gene, which has emerged as a central transcription factor or gene switch in many different human cancers.  His laboratory established the first mechanistic link between the MYC cancer gene and cellular energy metabolism, contributing to the concept that genetic alterations in cancers re-program fuel utilization by tumors and render cancers addicted to certain fuel sources. His laboratory is now exploiting these concepts for therapeutic targeting of cancer cell metabolism as a new way to treat cancer. Ongoing interests of the Dang lab include MYC oncogene function in rewiring metabolism, the effects of oncogene and hypoxic stress on the circadian molecular clock, MYC oncogene effects on metabolism and immunity and MYC and metabolic vulnerabilities of cancers.

Staff

Staff Scientists

Brian Altman, Ph.D.

Associate Staff Scientists

Tianying Jiang, Ph.D.
Zachary Stine, Ph.D.

Postdoctoral Fellows

Adam Wolpaw, Ph.D.
Xue Zhang, Ph.D.

Predoctoral Trainees

Rebekah Brooks
Zandra Walton

Research Assistant

Patricia Brafford
May Dong

Selected Publications

Lu, Y., Hu, Z., Dang, C.V., et al. "MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels." Cancer Res. 2018 Jan 1;78(1):64-74. doi: 10.1158/0008-5472.CAN-17-0815. Epub 2017 Nov 27.

Yang, L., Zhang, Y., Shan, W., Hu, Z., Yuan, J., Pi, J., Wang, Y., Fan, L., Tang, Z., Li, C., Hu, X. Tanyi, J.L., Fan, Y., Huang, Q., Montone, K., Dang, C.V., Zhang, L. "Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition." Sci Transl Med. 2017 Jul 26;9(400). pii: eaal1645. doi: 10.1126/scitranslmed.aal1645.

Altman, B.J., Hsieh, A.L., Dang, C.V., et al. "MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells." Cell Metab. 2015 Dec 1;22(6):1009-19. doi: 10.1016/j.cmet.2015.09.003. Epub 2015 Sep 17.

Xiang, Y., Stine, Z.E., Dang, C.V., et al. "Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis." J Clin Invest. 2015 Jun;125(6):2293-306. doi: 10.1172/JCI75836. Epub 2015 Apr 27.

View Additional Publications